Back to Case Studies

Hinckley Allen Representing Royal DSM on $2.6 billion Pharma Transaction

Corporate & Business, Securities, Securities Litigation, Litigation, Environmental

Hinckley Allen is representing Royal DSM, a global life sciences and material sciences company client, in a $2.6 billion series of transactions that will combine Patheon, Inc. (TSX: PTI) and the DSM Pharmaceutical Products business group into a new company to be owned 51% by JLL Partners, a private equity firm,  and 49% by DSM. The combined company will be a leading global contract development and manufacturing company for the pharmaceutical industry.   

DSM Press Release